News
Atomwise Aims Awards
Welter Family Fellowship
Veronica Hubble, a graduate student in the Melander lab, is the first recipient of the Welter Family graduate fellowship for research on Cystic Fibrous. The Welter Family Fellowship in Science provides financial support to conduct research during the 2019 academic…
RESEARCHERS DEVELOP DRUG-TARGETING MOLECULES TO IMPROVE CANCER TREATMENT
Ara Parseghian Medical Research Conference
Members of the Warren Center in attendance at the annual Ara Parseghian Medical Research Conference in Tucson, AZ in early June.
Spring 2019 The Warren Roundup
As the 2018 academic year comes to an end, a summary of this year's accomplishments is provided in the annual Warren Roundup. First of all, several lead compounds have been identified by Notre Dame researchers and are undergoing preclinical evaluation, in hopes of identifying investigational new drugs…
Notre Dame's Warren Center for Drug Discovery collaborates with Perlara on screening platform for glycogen storage diseases
Perlara, a rare diseases drug discovery company based in the San Francisco Bay area, recently announced a collaboration called PerlQuest with the University of Notre Dame’s Warren Family Research Center for Drug Discovery and Development.
Notre Dame technology licensed worldwide: Hsiri Therapeutics enters into a license and research collaboration agreement with Shionogi &Co., Ltd. for the treatment of mycobacterial diseases
University of Notre Dame licensee Hsiri Therapeutics, Inc., with its corporate headquarters located in Media, PA, has entered into a license agreement with Shionogi & Co., Ltd. regarding a collaborative licensing, research and development program to…
New Hope for the Treatment of Diabetic Foot Ulcers
In America, more than a million people suffer from diabetic foot ulcers.
In Latin, SalvePeds means “saving feet.”
And in SalvePeds, a new IDEA Center startup managed and marketed by a team of graduate students at the University of Notre Dame, patients may soon…
Spring 2018 Warren Roundup Published
Welcome to the first edition of the Warren Roundup, wherein an attempt is made to summarize accomplishments by members of the Warren Family Research Center for Drug Discovery. In addition, you will find below a succinct summary of the services provided by each of the three scientific cores (synthesis,…
Indiana CTSI launching new program to engage Indiana residents in improving health through research
The Indiana Clinical and Translational Sciences Institute (CTSI), a research partnership among Indiana University, Purdue University and the University of Notre Dame, has launched a new program called “All IN for Health” to help grow public awareness of the state’s current health challenges and to invite the public’s participation into research studies taking place at our academic partner institutions.
Indiana CTSI Receives $33M NIH Grant to Improve Health Statewide, with Public’s Participation
Indiana’s preeminent research universities are collaborating through the Indiana Clinical and Translational Sciences Institute (CTSI), which has recently been awarded more than $33 million in renewed National Institutes of Health (NIH) funding for the next five years.
Brian Blagg appointed new director of Warren Center for Drug Discovery
Brian Blagg, Ph.D., currently the Lester and Betty Mitscher Professor of Medicinal Chemistry at the University of Kansas, will join the University of Notre Dame as the incoming director of the Warren Family Research Center for Drug Discovery and Development and the Charles Huisking Professor of Chemistry & Biochemistry, according to Mary E. Galvin, William K. Warren Dean of the College of Science.
Researchers Shed New Light on Influenza Detection
Researchers have discovered a way to make influenza visible to the naked eye, by engineering dye molecules to target a specific enzyme of the virus.
Apply Today for these open Indiana CTSI Grants
There are currently four open Indiana Clinical and Translational Sciences Institute grant opportunities.
The Indiana CTSI is seeking applicants for the Collaboration in Translational Research (CTR) Pilot Grant Program. The objective of the Indiana CTSI CTR pilot grant program is to foster and encourage collaboration across the Indiana CTSI partner institutions (IU, Purdue, and Notre Dame) and to initiate or continue translational research projects that have very strong and immediate potential to develop into larger, externally funded research programs, or generate novel intellectual property (IP).
Tuberculosis Research Sheds Light on Disease-related Protein
The WHO names Tuberculosis (TB) as one of the top 10 causes of death worldwide and over 95 percent of those deaths occur in low- and middle-income countries. To improve the global health community’s understanding of TB and provide information that could help treat it, Notre Dame researchers have developed a new strain of the bacteria along with a new method to better study this deadly disease.
Warren Center faculty member presents at the Solutions for Drug-Resistant Infections Conference (SDRI 2017)
Professsor Marv Miller presented the seminar, “Conjugation of an acinetobacter selective sideophore to Daptomycin generates a sideromycin with potent activity against acinetobacter baumannii” at the Antimicrobial Drug Discovery Symposium at the Solutions for Drug-Resistant…
ND Day 2017: Supporting the Warren Family Research Center for Drug Discovery & Development
The College is thrilled to announce that Brian Blagg (currently the Lester and Betty Mitscher Professor of Medicinal Chemistry at Kansas), will be joining the Department of Chemistry & Biochemistry this Fall and assuming the role of Director of the Warren Family Research Center for Drug Discovery…
WHO's list of Priority Pathogen's and Antibiotic Research in the Warren Center
Expanding new areas of rare disease research at Notre Dame
Coinciding with the World Rare Disease Day, Notre Dame acknowledges a recent, generous gift from Notre Dame parents David and Cathleen Reisenauer of Morgan Hill, Calif., which will allow the Warren Family Research Center for Drug Discovery and Development to initiate a new area of research, focusing on the rare disease glycogen storage disease type III (GSDIII), also known as Cori Disease.